Bristol-Myers Squibb-Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade

Group 1: Company Performance - Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, showing a -0.58% change from the previous day's closing price, which lagged behind the S&P 500's daily gain of 0.16% [1] - Over the past month, shares of Bristol Myers Squibb gained 0.28%, outperforming the Medical sector's loss of 5.31% and the S&P 500's loss of 2.7% [1] Group 2: Upcoming Earnings - The company's earnings report is scheduled for February 6, 2025, with analysts expecting earnings of$ 1.46 per share, indicating a year-over-year decline of 14.12% [2] - The Zacks Consensus Estimate for revenue projects net sales of $11.6 billion, reflecting a 1.05% increase from the year-ago period [2] Group 3: Analyst Estimates and Rankings - Recent changes to analyst estimates for Bristol Myers Squibb are important as they reflect the shifting dynamics of short-term business patterns [3] - The Zacks Rank system, which includes estimate changes, currently ranks Bristol Myers Squibb at 2 (Buy), with a 0.29% rise in the Zacks Consensus EPS estimate over the past month [5] Group 4: Valuation Metrics - Bristol Myers Squibb is trading at a Forward P/E ratio of 7.9, which is a discount compared to the industry average Forward P/E of 22.58 [6] - The company has a PEG ratio of 1.98, compared to the Medical - Biomedical and Genetics industry's average PEG ratio of 1.5 [6] Group 5: Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 64, placing it in the top 26% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]